Clinical Research Updates

Advances in Immunosupressive Therapy for Solid Organ Transplantation

Long-Term Management Strategies to Improve Patient Outcomes

Management Guidelines

2012 Practice Guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation

KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients, 2009

General Resources

American Society of Transplantation

The American Society of Transplantation was founded in 1982 and is an organization of more than 3000 professionals dedicated to advancing the field of transplantation and improving patient care by promoting research, education, advocacy, and organ donation.

The Transplantation Society

The Transplantation Society is a Non-Governmental Organization (NGO) which serves as an international forum for the world-wide advancement of organ transplantation. 

The National Kidney Foundation

The National Kidney Foundation is the leading organization in the U.S. dedicated to the awareness, prevention and treatment of kidney disease for hundreds of thousands of healthcare professionals, millions of patients and their families, and tens of millions of Americans at risk.

American Liver Foundation

The American Liver Foundation was created in 1976 by the American Association for the Study of Liver Disease (AASLD) to facilitate, advocate and promote education, support and research for the prevention, treatment and cure of liver disease.

Suggested Readings

Immune monitoring post liver transplant.

Sood S, Testro AG. World J Transplant. 2014;4(1):30-39.

Immunosuppressive drug therapy.

Hartono C, et al. Cold Spring Harb Perspect Med. 2013;3(9):a015487.

Calcineurin inhibitor–free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized Spare-the-Nephron Trial.

Teperman L, et al. Liver Transpl. 2013;19:675-689.

Are calcineurin inhibitors-free regimens ready for prime time?

Vincenti F. Kidney Int. 2012;82(10):1054-1060.

TOR signaling in growth and metabolism.

Wullschleger S, et al. Cell. 2006;124(3):471-484.

Review of the proliferation inhibitor everolimus.

Nashan B. Expert Opin Investig Drugs. 2002;11(12):1845-1857.

Sirolimus: its discovery, biological properties, and mechanism of action.

Sehgal SN. Transplant Proc. 2003;35(suppl 3):7S-14S.

Identifying biomarkers as diagnostic tools in kidney transplantation.

Mas VR, et al. Expert Rev Mol Diagn. 2011;11(2):183-196.

Urinary-cell mRNA profile and acute cellular rejection in kidney allografts.

Suthanthiran M, et al. N Engl J Med. 2013;369(1):20-31.

Advances in Immunosuppressive Therapy for Solid Organ Transplantation

Long-term Management Strategies to Improve Patient Outcomes

Relevant Resources

Clinical Updates in Systemic Lupus Erythematosus

Improved Diagnostic and Management Strategies

Clinical Updates on the Management of Gout

Evidence-Based Strategies for Improved Patient Outcomes

Managing Gout in Primary Care

Evolving Strategies for Diagnosis and Long-Term Management

Improving Outcomes in Rheumatoid Arthritis

Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms

Clinical Updates in Rheumatoid Arthritis

Evolving Treatment Algorithms and Expert Perspectives on Biosimilars

Going Deeper on Atopic Dermatitis

Pathophysiology to the Management of Moderate-to-Severe Disease

Looking Beneath The Surface In Atopic Dermatitis

Targeting Immune Dysregulation and Delivering Comprehensive Care

Evolving Treatment Paradigms For Rheumatoid Arthritis

Translating Comprehensive Patient Evaluations Into Personalized Therapy

Clinical Updates in Rheumatoid Arthritis

New Perspectives on Targeting Remission and Individualizing Therapy

A Better Look at Rheumatoid Arthritis

Using Imaging to Improve Patient Outcomes

Clinical Issues in Rheumatoid Arthritis

Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs

Pathways to Better Outcomes in Systemic Lupus Erythematosus

Translating Pathophysiology into Targeted Treatments

The Big Picture of IBD

An Interactive Experience Highlighting Recent Clinical Advances

Clinical Issues in Rheumatoid Arthritis

Debates & Discussions on the Evolving Role of JAK Inhibitors

Clinical Issues in Rheumatoid Arthritis

The Evolving Role of JAK Inhibitors

JAKi in RA Practice

Unpacking the Evidence for Their Use Today and Tomorrow

What’s New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

Expert Views on the Changing Landscape in RA

The Increasing Role of JAK Inhibitors

Updates in Systemic Lupus Erythematosus

Unlocking Novel Paths to Patient Care

Swimming Upstream in Severe Asthma

New Pathways to Patient Management

Optimizing Advanced Therapies in Ulcerative Colitis: Is Your Practice Up to Date?

A Focus on Clinical Evidence and Guideline Recommendations

Cause for Alarm

New Avenues to the Management of Severe Asthma

Maybe It’s NOT Mechanical Back Pain

Getting on the Fast Track to Identify AxSpA

Finding the Path in Eosinophilic Esophagitis

Interdisciplinary Strategies for Adult and Pediatric Patients

Answering the Call

Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema

Targeting Clear Horizons

Finding the Path in Chronic Rhinosinusitis with Nasal Polyps

Choosing Your Path in Systemic Lupus Erythematosus

From Patient Evaluations to New Targeted Therapies

Buffing Up on New and Emerging ART

A Look at the Changing HIV Playing Field

PrEParing to End the Epidemic

Optimizing HIV Prevention in Primary Care